Last reviewed · How we verify
Minocycline plus tretinoin — Competitive Intelligence Brief
marketed
Tetracycline antibiotic + retinoid combination
Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin)
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Minocycline plus tretinoin (Minocycline plus tretinoin) — Derm Research @ 888 Inc.. Minocycline is a tetracycline antibiotic with anti-inflammatory properties, while tretinoin is a retinoid that promotes skin cell turnover and reduces sebum production; together they target bacterial infection and inflammation in acne.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Minocycline plus tretinoin TARGET | Minocycline plus tretinoin | Derm Research @ 888 Inc. | marketed | Tetracycline antibiotic + retinoid combination | Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Tetracycline antibiotic + retinoid combination class)
- Derm Research @ 888 Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Minocycline plus tretinoin CI watch — RSS
- Minocycline plus tretinoin CI watch — Atom
- Minocycline plus tretinoin CI watch — JSON
- Minocycline plus tretinoin alone — RSS
- Whole Tetracycline antibiotic + retinoid combination class — RSS
Cite this brief
Drug Landscape (2026). Minocycline plus tretinoin — Competitive Intelligence Brief. https://druglandscape.com/ci/minocycline-plus-tretinoin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab